Antibody

MedMira Announces Exclusive Distribution Partnership with Webb Diagnostic Technologies and Initial Order for REVEALCOVID-19™ Total Antibody Test in the U.S.

Wednesday, May 27, 2020 - 6:00pm

HALIFAX, Nova Scotia, May 27, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMiras REVEALCOVID-19 Total Antibody Test.

Key Points: 
  • HALIFAX, Nova Scotia, May 27, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMiras REVEALCOVID-19 Total Antibody Test.
  • Webb Diagnostic Technologies has placed the first order with the purchase value of approximately CDN$3.5 million.
  • REVEALCOVID-19 Total Antibody Test can detect antibodies to SARS-CoV-2, the virus that causes COVID-19, in the human serum, plasma and whole blood.
  • Webb Diagnostic Technologies (www.webbdx.com) has built an extensive sales and marketing team who will certainly drive our business forward.

Pacific Neuropsychiatric Specialists to Offer Discounted COVID-19 Antibody Testing

Wednesday, May 27, 2020 - 4:15pm

Pacific Neuropsychiatric Specialists (PNS) will begin offering COVID-19 antibody testing at various locations throughout Orange County.

Key Points: 
  • Pacific Neuropsychiatric Specialists (PNS) will begin offering COVID-19 antibody testing at various locations throughout Orange County.
  • Testing will be done in-office via blood sample from a finger prick; results will be available in approximately 15 minutes.
  • As your Orange County Psychiatry Provider, we have come to terms that the coronavirus (COVID-19) is part of the new reality.
  • In addition to offering COVID-19 antibody testing, we have opened up our practice to Spanish speaking clients, continued Dr. Alva.

BioDot Accelerates Manufacturing to Help Customers Meet Global COVID-19 Testing Demand

Wednesday, May 27, 2020 - 1:00pm

To support increasing demand globally for COVID-19 testing, BioDot has compressed production times for most new lateral flow dispensing platforms from months to four to six weeks.

Key Points: 
  • To support increasing demand globally for COVID-19 testing, BioDot has compressed production times for most new lateral flow dispensing platforms from months to four to six weeks.
  • BioDot is operating 7 days a week to meet demand from global diagnostics manufacturers, including contract development manufacturing organizations.
  • Worldwide, more than 50 companies are producing or developing COVID-19 antibody tests using BioDot technology.
  • BioDot, founded in 1994, is based in Irvine, Calif. and has international offices in Europe and Asia.

AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform

Wednesday, May 27, 2020 - 10:00am

AbCellera announced today that it has closed a US$105 million Series B financing.

Key Points: 
  • AbCellera announced today that it has closed a US$105 million Series B financing.
  • With the proceeds of the financing, AbCellera will expand its capacity and invest in technologies that complement and extend its proprietary antibody discovery engine.
  • AbCellera screens, selects, and analyzes millions of naturally produced antibodies to find next-generation drug candidates.
  • By accelerating the arduous and unpredictable process of antibody drug discovery with rigorous machine learning and data science, AbCellera enhances the entire biologics ecosystem, from small biotechs to global pharmaceutical companies.

Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting

Wednesday, May 27, 2020 - 1:13am

Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.

Key Points: 
  • Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
  • Immuteps current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 protein (LAG-3Ig) based on the LAG-3 immune control mechanism.
  • Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immuteps large pharmaceutical partners.

Xencor to Present at Upcoming Investor Conferences

Tuesday, May 26, 2020 - 9:01pm

A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

Key Points: 
  • A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
  • Currently, 17 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.

MeMD Enables Consumers, Businesses to Order COVID-19 Antibody Testing

Tuesday, May 26, 2020 - 5:30pm

Right now, that means making antibody testing more accessible and helping our clients and patients navigate the ever-evolving testing and return-to-work landscapes.

Key Points: 
  • Right now, that means making antibody testing more accessible and helping our clients and patients navigate the ever-evolving testing and return-to-work landscapes.
  • Innovation and breakthroughs in testing are happening by the minute, said Dr. Nicholas Lorenzo, chief medical officer for MeMD.
  • At MeMD, we are keeping pace with these innovations and enabling people to order the latest testing options available.
  • Heres how the process for COVID-19 antibody testing works:
    To request an order for an antibody test, consumers can set up a visit online, 24/7.

Gritstone Oncology Adopts Genedata Biopharma Platform to Accelerate Development of TCR and Bispecific Antibody Therapeutics

Tuesday, May 26, 2020 - 3:30pm

For instance, we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization," said Jonah Rainey, Ph.D., Head of Antibody Therapeutics at Gritstone Oncology.

Key Points: 
  • For instance, we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization," said Jonah Rainey, Ph.D., Head of Antibody Therapeutics at Gritstone Oncology.
  • Gritstone Oncology will use Genedata Biologics, a purpose-built enterprise platform for biopharma R&D, to design, engineer, and validate next-generation antibody therapeutic molecules such as bispecific antibodies.
  • Using the platform, Gritstone will automate R&D workflows, including molecular biology, screening, engineering, cloning, expression, purification, and analytics processes.
  • "The Genedata Biopharma Platform is a game changer in biopharma R&D.

Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies

Tuesday, May 26, 2020 - 3:11pm

The paper, titled A human neutralizing MAb targeting the receptor binding site of SARS-CoV-2 (Shi et al.

Key Points: 
  • The paper, titled A human neutralizing MAb targeting the receptor binding site of SARS-CoV-2 (Shi et al.
  • The article reports the identification and characterization of two specific human monoclonal antibodies (CA1 and CB6) isolated from a recovered COVID-19 patient.
  • While both antibodies demonstrated substantial neutralization activity in vitro against SARS-CoV-2, CB6 exhibited superior neutralizing activities.
  • Lilly is proud to have partnered with Junshi Biosciences to develop CB6 as a potential treatment for COVID-19.

CosmetiCare to Offer COVID-19 Antibody Testing

Tuesday, May 26, 2020 - 3:00pm

To help better serve its community during the current COVID-19 pandemic, CosmetiCare , an award-winning cosmetic plastic surgery center and medspa, is now offering COVID-19 antibody testing at its Newport Beach location.

Key Points: 
  • To help better serve its community during the current COVID-19 pandemic, CosmetiCare , an award-winning cosmetic plastic surgery center and medspa, is now offering COVID-19 antibody testing at its Newport Beach location.
  • I saw an opportunity to assist our local Orange County community by providing antibody tests, said Dr. Michael Niccole, founder of CosmetiCare.
  • In addition to its antibody testing service, CosmetiCare also has partnered with OC-based Goldsheep Clothing in its fight against COVID-19, to create protective face masks.
  • To learn more about CosmetiCares COVID-19 antibody testing, visit www.cosmeticare.com/covid19-antibody-test
    ABOUT COSMETICARE: CosmetiCare, an award-winning cosmetic plastic surgery center and med spa based in Orange County, Calif., knows a thing or two about the latest, most innovative aesthetic procedures on the market.